Skip to main content
OpenTrials
Completed

NCT Number: NCT03812705

Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD

The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD). The patient will cease antibiotics treatment 1 day before FMT, and stop taking food 6 hours before FMT. Patients will be given Ondansetron intravenously 1 hour before FMT. Patients will be injected 200~300 ml fecal microbiome fluid to left colon by Colonoscopy or duodenum through duodenal tube by gastroscopy. If patient's condition is stable or improved within 1 week, second FMT may be performed 1 week later, up to 4 times will be performed if patient response. If patient's condition is not improved after the second FMT, ceasing FMT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

14 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Shanghai Jiao Tong University Affilated First People's Hospital, Shanghai, Shanghai Municipality, China

Loading trial locations.

About this study

The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).

Inclusion criteria

  • Age>= 14 yrs ≤60 yrs.
  • Diagnosed with hematological diseases.
  • Recipients of allogeneic peripheral blood stem cell transplantation.
  • Steroid resistant/dependent acute intestinal graft-versus-host disease (GVHD) within 100 days post-transplantation. The definition of steroid resistant/dependent acute intestinal GVHD is progression within 3 days of starting treatment or an incomplete response by 7 days or recurrence after initial dose reduction.
  • ECOG score ≤2;
  • signed consent form.

Exclusion criteria

  • Complicated with uncontrolled severe infection except intestine and colon.
  • High risk of hemorrhage, dysfunction of coagulation, active gastrointestinal hemorrhage;
  • Absolute neutrophil count (ANC) <0.5×10e9/L or platelet count (PLT) < 20×10e9/L
  • Severe organ dysfunction, including heart failure, respiratory failure, renal failure, epilepsy or central nervous system dysfunction.
  • Participating other clinical trials.
  • Pregnant women.

Treatment:

  • Stop antibiotics treatment 1 day before FMT;
  • Fasting food 6 hours before FMT;
  • Give Ondansetron intravenously 1 hour before FMT for vomiting prevention;
  • Injection of 200~300 ml fecal microbiome fluid to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;
  • If patient's condition is stable or improved within 1 week, second FMT may be performed 1 week later, up to 4 times will be performed if patient response;
  • If patient's condition is not improved after the second FMT, stop FMT.

Major endpoint Response rate of acute gastrointestinal GVHD with 12 weeks after FMT, including complete response and partial response.

Minor endpoints:

  • Time to response of acute gastrointestinal GVHD;
  • Duration of response of acute gastrointestinal GVHD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age>= 14 yrs ≤60 yrs.
  • Diagnosed with hematological diseases.
  • Recipients of allogeneic peripheral blood stem cell transplantation.
  • Steroid resistant/dependent acute intestinal graft-versus-host disease (GVHD) within 100 days post-transplantation. The definition of steroid resistant/dependent acute intestinal GVHD is progression within 3 days of starting treatment or an incomplete response by 7 days or recurrence after initial dose reduction.
  • Eastern Cooperative Oncology Group (ECOG) score ≤2;
  • Signed consent form.

Exclusion criteria

  • Complicated with uncontrolled severe infection except intestine and colon.
  • High risk of hemorrhage, dysfunction of coagulation, active gastrointestinal hemorrhage;
  • Absolute neutrophil count (ANC) <0.5×10e9/L or platelet count (PLT) < 20×10e9/L
  • Severe organ dysfunction, including heart failure, respiratory failure, renal failure, epilepsy or central nervous system dysfunction.
  • Participating other clinical trials.
  • Pregnant women.

Treatment and study plan

fecal microbiome transplantation

Biological
  • Stop antibiotics treatment 1 day before fecal microbiome transplantation;
  • Fasting food 6 hours before fecal microbiome transplantation;
  • Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;
  • Perform fecal microbiome transplantation under colonoscopy or gastroscopy;
  • Perform up to 4 times if patient response;
  • Stop if no response after twice fecal microbiome transplantation.

Primary outcomes

  1. Response rate

    Time frame: 12 weeks within FMT

    Response rate of acute gastrointestinal GVHD after FMT, including complete response and partial response.

Secondary outcomes

  1. Time to response

    Time frame: 12 weeks within FMT

    Time to response of acute gastrointestinal GVHD

  2. Duration of response

    Time frame: 12 weeks within FMT

    Duration of response of acute gastrointestinal GVHD

Sponsors and collaborators

Lead sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Other

Registry information

Official study title

Fecal Microbiota Transplantation for the Treatment of Steroid Resistant/Dependent Acute Gastrointestinal Graft Versus Host Disease

Acronym: FEMITGIGVHD

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Jan 23, 2019
Registry last updated
Apr 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.